Rachel Nirsimloo

94P PRIMA vs real-world data: Patient characteristics and cancer outcomes

Sze Shin Low, S. Coulter, Alison A. McCormick, Jennifer R. Brown et autres

First-line niraparib maintenance was approved in Scotland following the PRIMA trial but approval was broader than trial eligibility. This study reports real-world data compared with the PRIMA population.

gb (code pays fourni par la source)

A phase Ib, open-label trial of MOv18 IgE in patients with advanced ovarian cancer.

Rebecca Kristeleit, Bristi Basu, Rowan Miller, J. L. Mesías Iglesias et autres

TPS5625 Background: All antibodies currently approved for cancer therapy are monoclonal IgGs. MOv18 IgE is a first-in-class therapeutic IgE antibody to have entered the clinic, successfully completing a Phase I trial in patients with advanced solid tumours. MOv18 IgE targets folate receptor …

gb (code pays fourni par la source)

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma

Yasushi Iida, Michael Churchman, Robert L. Hollis, Sarah E. Taylor et autres

OBJECTIVE: Clear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, however up to 30 % of low-stage cases relapse within five years. The benefit of adjuvant chemotherapy in early-stage disease (FIGO IA-IC1) remains uncertain. This study aimed to identify …

jp, gb (code pays fourni par la source)

Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer

Joanna M Porter, Michael Churchman, Ian Croy, C. Gourley et autres

BACKGROUND: Antibody-drug conjugates (ADCs) are emerging anti-cancer agents. The folate receptor alpha (FOLRα)-directed ADC mirvetuximab soravtansine recently demonstrated clinical activity in platinum-resistant ovarian cancer, with other ADCs currently in development. The relative expression of FOLRα and other ADC targets is largely unknown …

gb (code pays fourni par la source)

Corrigendum to ‘A Phase Ib, Open-Label Trial Of MOv18 IgE In Patients With Advanced Ovarian Cancer’ [International Journal of Gynecological Cancer Volume 35, Issue 2 Supplement 1 (2025) #809]

Rebecca Kristeleit, Bristi Basu, Rowan Miller, J.M. Iglesias et autres

gb (code pays fourni par la source)

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma

Yasushi Iida, Michael Churchman, Robert L. Hollis, Sarah E. Taylor et autres

Abstract Objective Clear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, but up to 30% of low-stage cases relapse within five years. The benefit of adjuvant chemotherapy for low-stage CCOC (FIGO stage IA-IC1) remains uncertain. This study aimed to …

jp, gb (code pays fourni par la source)

Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer

Rebecca Kristeleit, Michael-John Devlin, Andrew R. Clamp, Charlie Gourley et autres

Importance: Advanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with programmed cell death 1 protein (PD-1) inhibitors reported in CCGC merits further investigation. Objective: To assess the clinical …

gb (code pays fourni par la source)

A Phase Ib, Open-Label Trial Of MOv18 IgE In Patients With Advanced Ovarian Cancer

Bristi Basu, Rowan Miller, J.M. Iglesias, Andrew Calam et autres

gb (code pays fourni par la source)

Combined Genomic and Molecular Analysis Defines Prognostic Markers of Relapse in Stage Ia-Ic1 Clear Cell Ovarian Carcinoma

Yasushi Iida, Michael Churchman, Robert L. Hollis, Sarah E. Taylor et autres

gb, jp (code pays fourni par la source)

Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome

John P. Thomson, Robert L. Hollis, Juliette van Baal, Narthana Ilenkovan et autres

OBJECTIVES: Low-grade serous ovarian carcinoma (LGSOC) is a distinct, rare, ovarian cancer type characterised by younger patient age and intrinsic chemoresistance. Understanding the molecular landscape is crucial for optimising targeted therapy. METHODS: Genomic data from whole exome sequencing of tumour tissue was …

gb, nl (code pays fourni par la source)

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma

Robert L. Hollis, John P. Thomson, Juliette van Baal, Narthana Ilenkovan et autres

Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor expression patterns and MAPK gene mutation status, remains poorly …

gb, nl (code pays fourni par la source)

2022-RA-1276-ESGO Pembrolizumab monotherapy for advanced clear cell gynaecological cancer: phase II PEACOCC trial

Rowan Miller, Andrew R. Clamp, Charlie Gourley, René L. Roux et autres

gb (code pays fourni par la source)